A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002262
|United States, California|
|San Francisco AIDS Clinic / San Francisco Gen Hosp|
|San Francisco, California, United States, 941102859|